← Back to headlines
Xenon Anticipates AZK NDA Submission in Q3 2026
Xenon Pharmaceuticals expects to submit its New Drug Application (NDA) for AZK in the third quarter of 2026, with a projected launch timing at the end of 2027 or early 2028.
8 May, 07:42 — 8 May, 07:42
Sources
Showing 1 of 1 sources
